Personalized methods of treating cancer
View Patent ↗Disclosed herein are dietary compositions that are substantially devoid of at least cysteine or a salt thereof for use in treating a cancer. The dietary compositions and methods of the disclosure can be used to treat cancers that are MTAP-deficient, alone or in combination with a cancer therapy.
1. A method for treating a cancer having dysregulated polyamine metabolism in a subject in need thereof, wherein the cancer having dysregulated polyamine metabolism is breast cancer, colorectal cancer, pancreatic cancer, or brain cancer, the method comprising administering to the subject a therapeutically effective amount of a dietary product, wherein:
the dietary product comprises at most about 0.5% (w/w) of cysteine or cystine; the dietary product comprises at least about 7.5% (w/w) of methionine;
the therapeutically effective amount of the dietary product is from about 0.5 g/kg/day to about 1 g/kg/day; and
the subject is undergoing a cancer therapy for the cancer having dysregulated polyamine metabolism.
2. The method of claim 1 , wherein the cancer having dysregulated polyamine metabolism is breast cancer.
3. The method of claim 1 , wherein the cancer having dysregulated polyamine metabolism is colorectal cancer.
4. The method of claim 1 , wherein the cancer having dysregulated polyamine metabolism is pancreatic cancer.
5. The method of claim 1 , wherein the cancer having dysregulated polyamine metabolism has downregulated 5-methylthioadenosine phosphorylase (MTAP) expression.
6. The method of claim 1 , wherein the cancer having dysregulated polyamine metabolism has upregulated adenosylmethionine decarboxylase 1 (AMD1) expression.
7. The method of claim 1 , wherein the administering is oral.
8. The method of claim 1 , wherein the dietary product is devoid of cysteine or cystine.
9. The method of claim 8 , wherein the dietary product is devoid of cysteine or cystine, serine, and glycine.
10. The method of claim 9 , wherein the dietary product is further devoid of tyrosine and arginine.
11. The method of claim 1 , wherein the dietary product comprises more than about 10% (w/w) of methionine.
12. The method of claim 1 , wherein the cancer therapy is radiotherapy.
13. The method of claim 1 , wherein the cancer therapy is chemotherapy.
14. The method of claim 1 , wherein the cancer therapy further comprises administration of a therapeutically effective amount of a polyamine, a precursor of the polyamine, or an analog of the polyamine to the subject.
15. The method of claim 14 , wherein the therapeutically effective amount of the polyamine, the precursor of the polyamine, or the analog of the polyamine is from about 100 mg to about 5000 mg.
16. The method of claim 1 , comprising administering from about 100 mg to about 2000 mg of the methionine.
17. The method of claim 1 , comprising administering at most about 500 mg/day of the cysteine or cystine.
18. The method of claim 1 , wherein administering the dietary product to the subject increases efficacy of the cancer therapy in the subject by at least about 10% as compared to an efficacy of the cancer therapy in a comparable subject receiving the cancer therapy but not the dietary product.
19. The method of claim 1 , wherein administering the dietary product elevates cellular reactive oxygen species (ROS) levels.